Tehran University of Medical Sciences Iranian Journal of Allergy, Asthma and Immunology 1735-1502 15 2 2016 04 04 112 121 EN Tomic-Spiric Vesna Clinic for Allergology and Immunology, Clinical Centre of Serbia, Belgrade, Serbia AND Faculty of Medicine, University of Belgrade, Belgrade, Serbia Dizdarevic Denisa Clinic for Allergology and Immunology, Clinical Centre of Serbia, Belgrade, Serbia AND Faculty of Medicine, University of Belgrade, Belgrade, Serbia Jankovic Slavenka Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia Burazer Lidija Department of Allergy, Institute of Virology, Vaccines and Sera "Torlak", Belgrade, Serbia Barac Aleksandra Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia Bolpacic Jasna Clinic for Allergology and Immunology, Clinical Centre of Serbia, Belgrade, Serbia AND Faculty of Medicine, University of Belgrade, Belgrade, Serbia Djuric Vojislav Clinic for Allergology and Immunology, Clinical Centre of Serbia, Belgrade, Serbia AND Faculty of Medicine, University of Belgrade, Belgrade, Serbia Peric-Popadic Aleksandra Clinic for Allergology and Immunology, Clinical Centre of Serbia, Belgrade, Serbia AND Faculty of Medicine, University of Belgrade, Belgrade, Serbia Aleksic Aleksandra Department of Ear, Nose and Throat, University Hospital, Clinical Center of Banja Luka, Banja Luka, Bosnia and Herzegovina Bogic Mirjana Clinic for Allergology and Immunology, Clinical Centre of Serbia, Belgrade, Serbia AND Faculty of Medicine, University of Belgrade, Belgrade, Serbia 2015 10 25 2015 12 06 Sublingual allergen immunotherapy (SLIT) is considered to be safer and more convenient than subcutaneus immunotherapy. SLIT trials with house dust mites involving patients with allergic rhinitis (AR) and asthma reported discordant results. The aim of the study was to investigate the clinical efficacy and safety of SLIT with Dermatophagoides pteronyssinus (D.pt) extract produced in Serbia and patient’s satisfaction through open-label trial. Adult patients with allergic rhinitis were randomized into two groups: one received drugs and SLIT, while other received only drugs. Symptom score (SS), medication score (MS) and cumulative score (CS), skin prick tests (SPT) and serum level of D. pt specific IgE were assessed. One year after, the patients were re-evaluated. In total, 61 patients were enrolled in the study, but 52 of them were analyzed at the end of the year. CS (29.3%, p<0.001) and MS (54.3%, p<0.05) reduced significantly in the SLIT group. There was a significant improvement of MS and CS in the SLIT compared to control group (p<0.001 and p<0.05 respectively). There was no significant improvement of SS as well as specific slgE. Patients in the SLIT group were more satisfied with treatment (p<0.001). The incidence of mild adverse reaction was 38.4%. Specific lgG was not done. One year SLIT with D.pt extract was clinically efficient treatment in AR patients. https://ijaai.tums.ac.ir/index.php/ijaai/article/view/629 https://ijaai.tums.ac.ir/index.php/ijaai/article/download/629/619